Projects per year
Personal profile
Biography
Dakang Xu works in the Centre for Cancer Research at the Hudson Institute of Medical Research. The main focus of his research team is to characterise modulation of key regulators that affect inflammatory responses and tumour progression, through the function of immune cell subsets and cytokines in cancer and inflammatory diseases. This work has led to 40 peer-reviewed publications in high impact journals, including Nat Immunol, Immunity, Nat Commun, PNAS, EMBO J and Cancer Res. These include 15 papers as senior and corresponding author.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Research area keywords
- Immunity
- Cancer
- Inflammation
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 4 Finished
-
Targeting cytokine signalling in systemic lupus erythematosus
Sadler, A., Williams, B. & Xu, D.
1/01/18 → 31/12/21
Project: Research
-
Activating transcription factor 3 and cancer progression
Williams, B., Hannigan, G., Williams, E. & Xu, D.
National Health and Medical Research Council (NHMRC) (Australia)
1/01/14 → 31/12/17
Project: Research
-
The role of PLZF in regulating the antiviral activity of interferons
National Health and Medical Research Council (NHMRC) (Australia)
1/01/10 → 31/12/13
Project: Research
-
Large-scale comparative assessment of computational predictors for lysine post-translational modification sites
Chen, Z., Liu, X., Li, F., Li, C., Marquez-Lago, T., Leier, A., Akutsu, T., Webb, G. I., Xu, D., Smith, A. I., Li, L., Chou, K. C. & Song, J., Nov 2019, In: Briefings in Bioinformatics. 20, 6, p. 2267-2290 24 p., bby089.Research output: Contribution to journal › Article › Research › peer-review
52 Citations (Scopus) -
(−)-Epigallocatechin-3-gallate and EZH2 inhibitor GSK343 have similar inhibitory effects and mechanisms of action on colorectal cancer cells
Ying, L., Yan, F., Williams, B. R. G., Xu, P., Li, X., Zhao, Y., Hu, Y., Wang, Y., Xu, D. & Dai, J., 1 Jan 2018, In: Clinical and Experimental Pharmacology and Physiology. 45, 1, p. 58-67 10 p.Research output: Contribution to journal › Article › Research › peer-review
16 Citations (Scopus) -
PD-L1 expression is a prognostic factor in subgroups of gastric cancer patients stratified according to their levels of CD8 and FOXP3 immune markers
Ying, L., Yan, F., Meng, Q., Yu, L., Yuan, X., Gantier, M. P., Williams, B. R. G., Chan, D. W., Shi, L., Tu, Y., Ni, P., Wang, X., Chen, W., Zang, X., Xu, D. & Hu, Y., 20 Feb 2018, In: OncoImmunology. 7, 6, 11 p., e1433520.Research output: Contribution to journal › Article › Research › peer-review
22 Citations (Scopus) -
A non-canonical function of Ezh2 preserves immune homeostasis
Vasanthakumar, A., Xu, D., Lun, A. T. L., Kueh, A. J., van Gisbergen, K. P. J. M., Iannarella, N., Li, X., Yu, L., Wang, D., Williams, B. RG., Lee, S. C. W., Majewski, I. J., Godfrey, D. I., Smyth, G. K., Alexander, W. S., Herold, M. J., Kallies, A., Nutt, S. L. & Allan, R. S., 1 Apr 2017, In: EMBO Reports. 18, 4, p. 619-631 13 p.Research output: Contribution to journal › Article › Research › peer-review
44 Citations (Scopus) -
DLX1 acts as a crucial target of FOXM1 to promote ovarian cancer aggressiveness by enhancing TGF-β/SMAD4 signaling
Chan, D. W., Hui, W. W. Y., Wang, J. J., Yung, M. M. H., Hui, LMN., Qin, Y., Liang, RR., Leung, T. H. Y., Xu, D., Chan, KKL., Yao, K-M., Tsang, B. K. & Ngan, H. Y. S., 1 Mar 2017, In: Oncogene. 36, 10, p. 1404-1416 13 p.Research output: Contribution to journal › Article › Research › peer-review
Open AccessFile29 Citations (Scopus)